RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a...
Vous n'êtes pas connecté
RAHWAY, N.J.--(BUSINESS WIRE) August 8, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the Phase 3 KeyVibe-008 trial based on the recommendation of an independent Data...
RAHWAY, N.J.--(BUSINESS WIRE) September 4, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and EyeBio, a...
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
September 8, 2024 -- Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s...
9 September 2024 -- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival...